CollPlant Biotechnologies Ltd.
$0.37
▼
-0.92%
2026-04-21 06:04:01
collplant.com
NCM: CLGN
Explore CollPlant Biotechnologies Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.15 M
Current Price
$0.37
52W High / Low
$4.98 / $0.27
Stock P/E
—
Book Value
$0.47
Dividend Yield
—
ROCE
-141.54%
ROE
-1.18%
Face Value
—
EPS
$-0.94
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
39
Beta
0.94
Debt / Equity
46.8
Current Ratio
2.52
Quick Ratio
2.31
Forward P/E
-0.98
Price / Sales
2.32
Enterprise Value
$2.76 M
EV / EBITDA
-0.26
EV / Revenue
1.17
Rating
Hold
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CDT Equity Inc. | $3.35 | — | $16.81 M | — | 230.89% | 491.09% | $3,030 / $2.6 | $83.78 |
| 2. | Cabaletta Bio, Inc. | $3.31 | — | $382.95 M | — | -149.87% | -1.27% | $3.78 / $1.06 | $1.11 |
| 3. | Candel Therapeutics, Inc. | $7.22 | — | $466.58 M | — | -41.46% | -64.58% | $7.25 / $4.34 | $0.95 |
| 4. | Elicio Therapeutics, Inc. | $12.2 | — | $224.43 M | — | -210.11% | 817.92% | $14.93 / $4.7 | $0.09 |
| 5. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
| 6. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
| 7. | NeurAxis, Inc. | $7 | — | $80.77 M | — | -216.78% | -2.85% | $7.97 / $1.33 | $0.32 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.06 M | 0.08 M | 0.18 M | 2.06 M | 0.16 M | — |
| Operating Profit | -3.15 M | -3.51 M | -3.18 M | -1.65 M | -3.97 M | — |
| Net Profit | -3.21 M | -3.48 M | -3.35 M | -1.45 M | -3.88 M | — |
| EPS in Rs | -0.22 | -0.24 | -0.23 | -0.1 | -0.27 | -0.38 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.37 M | 0.52 M | 10.96 M | 0.3 M |
| Operating Profit | -11.48 M | -17.25 M | -7.51 M | -17.1 M |
| Net Profit | -11.49 M | -16.61 M | -7.02 M | -16.93 M |
| EPS in Rs | -0.8 | -1.15 | -0.49 | -1.17 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 10.79 M | 18.71 M | 34.13 M | 37.77 M |
| Total Liabilities | 4.7 M | 5.25 M | 5.79 M | 5.49 M |
| Equity | 6.08 M | 13.46 M | 28.34 M | 32.28 M |
| Current Assets | 6.75 M | 13.18 M | 28.02 M | 31.66 M |
| Current Liabilities | 2.67 M | 2.97 M | 3.25 M | 3.1 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.42 M | -14.09 M | -2.76 M | -13.7 M |
| Investing CF | -0.03 M | -0.54 M | -1.16 M | 28.92 M |
| Financing CF | 3.1 M | 0.01 M | 1.11 M | 1.87 M |
| Free CF | -9.45 M | -14.58 M | -3.72 M | -15.01 M |
| Capex | -0.03 M | -0.48 M | -0.95 M | -1.32 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -95.3% | 3565.22% | — | — |
| Earnings Growth % | -136.63% | 58.53% | — | — |
| Profit Margin % | -3225.05% | -64.05% | -5660.54% | — |
| Operating Margin % | -3349.71% | -68.55% | -5718.06% | — |
| Gross Margin % | -215.53% | 81.83% | -33.78% | — |
| EBITDA Margin % | -3148.16% | -58.49% | -5358.19% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.